PCSK9 Inhibitors (e.g., evolocumab, alirocumab)

Type: drug

Status: FDA Approved, EMA Approved

Developer: Amgen (evolocumab), Regeneron/Sanofi (alirocumab)

Breakthrough Summary

No summary available.

Mechanism of Action

Details pending.

Year: 2026